Results 81 to 90 of about 88,199 (267)

Renoprotective Effects of Hydroxychloroquine and Folinic Acid via ET-1 and NLRP3 Modulation in Reducing Tubular Injury in A Rabbit Model of Methanol-induced Acute Kidney Injury

open access: yesIndonesian Biomedical Journal
BACKGROUND: Methanol intoxication is associated with significant morbidity and mortality, particularly when acute kidney injury (AKI) developed. Emerging evidence implicates Endothelin-1 (ET-1) and Nucleotide-binding domain leucine-rich repeat-containing
Prayuda Prayuda   +5 more
doaj   +1 more source

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients

open access: yesCardiovascular Therapeutics, 2021
Background. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death.
Seyed Parsa Eftekhar   +5 more
doaj   +1 more source

Hydroxychloroquine shortage [PDF]

open access: yesBritish Dental Journal, 2020
Patel, J., Coulthard, P.
openaire   +2 more sources

Mucocutaneous disease activity and damage accrual in systemic lupus erythematosus: analyses from the Asia‐Pacific Lupus Collaboration longitudinal cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective This research article aims to describe the prevalence, associations and health‐related quality‐of‐life (HRQoL) impact of mucocutaneous features of SLE. Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analysed (2013‐2021). Mucocutaneous activity (MC‐A) items were rash, alopecia and mucosal ulcers; defined by the SLEDAI‐2K ...
Amanda M Saracino   +42 more
wiley   +1 more source

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.

open access: yesPLoS ONE, 2020
Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients.
Andrew Ip   +31 more
doaj   +1 more source

Toxidermie médicamenteuse sous hydroxychloroquine pour traitement systémique d´un syndrome de Goujerot Sjögren primaire: rapport de cas

open access: yesThe Pan African Medical Journal, 2021
Nous rapportons un cas d´exanthème maculo-papuleux apparu après une semaine de prise de l´hydroxychloroquine 400mg prescrite pour une atteinte articulaire d´un syndrome de Goujerot Sjögren primaire chez une patiente de 41 ans.
Ansumana Mohammed Keita   +3 more
doaj   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker   +14 more
wiley   +1 more source

Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Vitamin D Supplementation and Hydroxychloroquine: Two Case Reports [PDF]

open access: yes, 2013
Introduction: Immune thrombocytopenic purpura is thought to be characterized by an immune response against the host’s own platelets. If the thrombocytopenia is severe, patients are initially treated with high-dose steroids.
Bockow, Barry, Bockow, Tamara B
core   +1 more source

Real‐World Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel   +6 more
wiley   +1 more source

Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis [PDF]

open access: yes, 2018
Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107 ...
Achuthan   +44 more
core   +1 more source

Home - About - Disclaimer - Privacy